Insider Transactions in Q2 2024 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-7.04%
|
$1,073,880
$471.72 P/Share
|
|
Jun 12
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-6.58%
|
$1,089,840
$478.0 P/Share
|
|
Jun 12
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
7,288
-31.33%
|
$3,483,664
$478.0 P/Share
|
|
Jun 11
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,824
-22.68%
|
$3,282,344
$481.96 P/Share
|
|
Jun 05
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Bona fide gift
|
Indirect |
4,600
-100.0%
|
-
|
|
Jun 03
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,250
-6.45%
|
$1,495,000
$460.0 P/Share
|
|
Jun 03
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,175
-4.24%
|
$1,000,500
$460.0 P/Share
|
|
May 31
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,250
-4.2%
|
$1,001,250
$445.0 P/Share
|
|
May 30
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,350
-4.21%
|
$1,031,650
$439.11 P/Share
|
|
May 29
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-6.17%
|
$1,014,600
$445.56 P/Share
|
|
May 28
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,250
-6.06%
|
$1,475,500
$454.79 P/Share
|
|
May 24
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
1,565
-1.27%
|
$715,205
$457.0 P/Share
|
|
May 24
2024
|
Reshma Kewalramani CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,565
+1.26%
|
$292,655
$187.53 P/Share
|
|
May 22
2024
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
7,073
-15.03%
|
$3,168,704
$448.0 P/Share
|
|
May 22
2024
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,073
+13.06%
|
$657,789
$93.51 P/Share
|
|
May 20
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-11.13%
|
$6,795,294
$447.0 P/Share
|
|
May 15
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
69
-0.14%
|
$29,670
$430.93 P/Share
|
|
May 15
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
32
-0.06%
|
$13,760
$430.93 P/Share
|
|
May 15
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
54
-0.21%
|
$23,220
$430.93 P/Share
|
|
May 15
2024
|
Jennifer Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
922
+50.0%
|
-
|
|
May 14
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
14,112
+31.93%
|
-
|
|
May 02
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
467
-9.53%
|
$187,734
$402.95 P/Share
|
|
May 01
2024
|
Suketu Upadhyay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-31.34%
|
-
|
|
May 01
2024
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.17%
|
-
|
|
May 01
2024
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
501
+23.43%
|
-
|
|
May 01
2024
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-32.41%
|
-
|
|
May 01
2024
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.74%
|
-
|
|
May 01
2024
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+16.96%
|
-
|
|
May 01
2024
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+13.67%
|
-
|
|
Apr 02
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
240
-3.1%
|
$100,560
$419.0 P/Share
|
|
Apr 01
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-2.82%
|
$94,050
$418.1 P/Share
|